Iovance Biotherapeutics, Inc. IOVA Business Segments — Royalty Expense

Similar metrics at other companies

TVTXReportable Segment — Royalty expense

$24.82M+99.7%

AMGNReportable Segment — Royalty Expense

$564M+28.2%

QURESingle Reportable — Royalty Financing Agreement Interest Expense

$12.62M-5.2%

ACADReportable Segment Aggregation Before Other Operating — Royalty Expense

$13.13M+17.4%

ONDSRoyalty Expense

$85.5K+23.5%

CAPRSingle Reportable — Nonoperating Income Expense

$2.83M+379%

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s business segments — royalty expense?

Iovance Biotherapeutics, Inc. (IOVA) reported business segments — royalty expense of $2.65M in Q1 2026.

How has Iovance Biotherapeutics, Inc.'s business segments — royalty expense changed year-over-year?

Iovance Biotherapeutics, Inc.'s business segments — royalty expense increased by 99.8% year-over-year, from $1.33M to $2.65M.

What does business segments — royalty expense mean?

This represents the contractual payments made to third parties for the use of intellectual property or licensed technologies essential to the company's product offerings. It is a critical component of the cost structure that impacts the overall gross margin of the segment.